Unexpected cutaneous toxicity of IGEV regimen in patients with Hodgkin lymphoma.

Ewa Paszkiewicz-Kozik,Joanna Romejko-Jarosinska,B. Brzeska,W. Osiadacz,Monika Świerkowska-Czeneszew,Michal Osowiecki,Agnieszka Druzd-Sitek,J. Tajer,E. Wojciechowska-Lampka,Jan Walewski

Unexpected cutaneous toxicity of IGEV regimen in patients with Hodgkin lymphoma.

2011

Ewa Paszkiewicz-Kozik
Joanna Romejko-Jarosinska
B. Brzeska
W. Osiadacz
Monika Świerkowska-Czeneszew
Michal Osowiecki
Agnieszka Druzd-Sitek
J. Tajer
E. Wojciechowska-Lampka
Jan Walewski

e18543 Background: IGEV (ifosfamide, gemcitabine, vinorelbine, and prednisolone) is an active regimen increasingly used in relapsed/refractory Hodgkin lymphoma (HL) before autologous stem cell tran...

Keywords:

Lymphoma
Regimen
Pathology
Toxicity
Medicine
Refractory Hodgkin Lymphoma
Internal medicine
Ifosfamide
Stem cell
Vinorelbine
Gemcitabine
Prednisolone
Oncology
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations